Cargando…
Corrigendum: Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research
The authors wish to make corrections to their article: Nicola S, Rolla G, Brussino L. Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research. Drugs in Context 2019; 8: 212605. DOI: 10.7573/dic.212605
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
BioExcel Publishing Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048101/ https://www.ncbi.nlm.nih.gov/pubmed/32158478 http://dx.doi.org/10.7573/dic.2019-11-2 |
Ejemplares similares
-
Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research
por: Nicola, Stefania, et al.
Publicado: (2019) -
Corrigendum to “Assessment of 105 Patients with Angiotensin Converting Enzyme-Inhibitor Induced Angioedema”
por: Rasmussen, Eva Rye, et al.
Publicado: (2018) -
Corrigendum to: ACE inhibitor-induced small bowel angioedema, mimicking an acute abdomen
por: Parreira, Rafaela, et al.
Publicado: (2020) -
Corrigendum to “Those Who Hear Music: Three Cases on Musical Hallucinations”
por: Doluweera, Yasira, et al.
Publicado: (2021) -
Cinryze(™) as the first approved C1 inhibitor in the USA for the treatment of hereditary angioedema: approval, efficacy and safety
por: Lunn, Michael, et al.
Publicado: (2010)